<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867413476757</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867413476757</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correspondence</subject>
<subj-group subj-group-type="heading">
<subject>Letters</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cerebrolysin and its emerging clinical applications in psychiatry</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kapoor</surname><given-names>Shailendra</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0004867413476757">S Kapoor, 74 Crossing Place, Mechanicsville, VA, USA. Email: <email>shailendrakapoor@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>7</issue>
<fpage>685</fpage>
<lpage>685</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>To the Editor</p>
<p>I read with great interest the recent article by <xref ref-type="bibr" rid="bibr8-0004867413476757">Xiao et al. (2012)</xref>. Cerebrolysin may have a number of clinical benefits in the treatment of psychiatric disorders.</p>
<p>Cerebrolysin, when administered in conjunction with neuroleptics, can attenuate cognitive dysfunction in patients with mild moderate autism. The combination can also help to ameliorate behavioural disorders in patients with mild moderate autism to a certain extent. Fine motor function is improved by about 0.10 years while attention during performance of tasks is improved by about 0.34 years (<xref ref-type="bibr" rid="bibr5-0004867413476757">Radzivil and Bashina, 2006</xref>). Cerebrolysin seems to be more effective in patients with Asperger’s syndrome in comparison to patients with childhood autism. For instance, <xref ref-type="bibr" rid="bibr2-0004867413476757">Krasnoperova et al. (2003)</xref> reported positive benefit from cerebrolysin therapy in nearly all patients with Asperger’s syndrome in contrast to clinical benefit in 89% of patients with autism.</p>
<p>Similarly, in patients with Alzheimer’s disease cerebrolysin administration results in significant improvements in the global function as well as the ‘Change with Caregiver Input’ scale. Similarly, significant improvement is seen in the ‘Alzheimer’s disease Assessment Scale-Cognitive subscale’ (<xref ref-type="bibr" rid="bibr3-0004867413476757">Panisset et al., 2002</xref>). Patients with underlying Alzheimer’s disease also show improvement in the ‘Cornell Depression Scale’ (<xref ref-type="bibr" rid="bibr1-0004867413476757">Bae et al., 2000</xref>). For instance, <xref ref-type="bibr" rid="bibr3-0004867413476757">Panisset et al. (2002)</xref> showed that following 3 months of cerebrolysin therapy the response rate was 76% (CIBIC + responders) in the cerebrolysin group compared to 57% in the placebo group (<xref ref-type="bibr" rid="bibr3-0004867413476757">Panisset et al., 2002</xref>). Clinical benefit has been observed as long as 24 weeks after cessation of cerebrolysin therapy (<xref ref-type="bibr" rid="bibr6-0004867413476757">Ruether et al., 2002</xref>; <xref ref-type="bibr" rid="bibr7-0004867413476757">Ruther et al., 2000</xref>).</p>
<p>Side effects of psychotropic drugs such as dysuria can be ameliorated by concurrent cerebrolysin administration (<xref ref-type="bibr" rid="bibr4-0004867413476757">Panteleeva et al., 1999</xref>). In fact, nearly 74 % of patients with psychotropic-induced extrapyramidal side effects benefit from cerebrolysin therapy. Dysomnia also can be reduced by simultaneous cerebrolysin administration. Cardiac side effects are also decreased.</p>
<p>Common side effects of cerebrolysin therapy include weight loss and headaches; anxiety exacerbation may also occur. Despite these side effects, the clinical benefit of cerebrolysin makes it a remarkable agent with significant potency in psychiatric disorders. Clearly, there is a need for further large-scale studies to fully assess the full potential and efficacy of cerebrolysin.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of interest</label>
<p>The author reports no conflicts of interest. The author alone is responsible for the content and writing of the paper.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bae</surname><given-names>CY</given-names></name>
<name><surname>Cho</surname><given-names>CY</given-names></name>
<name><surname>Cho</surname><given-names>K</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease</article-title>. <source>Journal of the American Geriatrics Society</source>
 <volume>48</volume>: <fpage>1566</fpage>–<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr2-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krasnoperova</surname><given-names>MG</given-names></name>
<name><surname>Bashina</surname><given-names>VM</given-names></name>
<name><surname>Skvortsov</surname><given-names>IA</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>The effect of cerebrolysin on cognitive functions in childhood autism and in Asperger syndrome</article-title>. <source>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</source>
 <volume>103</volume>: <fpage>15</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr3-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panisset</surname><given-names>M</given-names></name>
<name><surname>Gauthier</surname><given-names>S</given-names></name>
<name><surname>Moessler</surname><given-names>H</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent</article-title>. <source>Journal of Neural Transmission</source> <volume>109</volume>: <fpage>1089</fpage>–<lpage>1104</lpage>.</citation>
</ref>
<ref id="bibr4-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panteleeva</surname><given-names>GP</given-names></name>
<name><surname>Bondar’</surname><given-names>VV</given-names></name>
<name><surname>Krasnikova</surname><given-names>NI</given-names></name>
<etal/></person-group>. (<year>1999</year>) <article-title>Cerebrolysin and magnesium-B6 in the treatment of side effects of psychotropic drugs</article-title>. <source>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</source> <volume>99</volume>: <fpage>37</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr5-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radzivil</surname><given-names>MG</given-names></name>
<name><surname>Bashina</surname><given-names>VM</given-names></name>
</person-group> (<year>2006</year>) <article-title>An effect of long-term cerebrolysin therapy in combination with neuroleptics on behavioral and cognitive disturbances in endogenous childhood autism</article-title>. <source>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</source> <volume>106</volume>: <fpage>21</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr6-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruether</surname><given-names>E</given-names></name>
<name><surname>Alvarez</surname><given-names>XA</given-names></name>
<name><surname>Rainer</surname><given-names>M</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin</article-title>. <source>Journal of Neural Transmission</source> <supplement>Suppl 62</supplement>: <fpage>265</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr7-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruther</surname><given-names>E</given-names></name>
<name><surname>Ritter</surname><given-names>R</given-names></name>
<name><surname>Apecechea</surname><given-names>M</given-names></name>
<etal/></person-group>. (<year>2000</year>) <article-title>Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy</article-title>. <source>Journal of Neural Transmission</source> <volume>107</volume>: <fpage>815</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr8-0004867413476757">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>S</given-names></name>
<name><surname>Xue</surname><given-names>H</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>46</volume>: <fpage>153</fpage>–<lpage>160</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>